FluoTech Biosciences is at the forefront of developing advanced therapeutic solutions for cardiovascular diseases, particularly atherosclerosis. Our proprietary FTB-728 nanoparticle platform offers unparalleled drug-loading capacity and precise targeting, revolutionizing how we approach disease treatment.
FluoTech Biosciences is a rapidly expanding biotechnology company dedicated to transforming healthcare through cutting-edge nanomaterial technologies. Founded in April 2024, we have established robust partnerships with leading institutions and secured funding from HKTECH300, Hong Kong’s premier technology startup program.
At FluoTech, we’re revolutionizing cardiovascular treatment with our FTB-728 platform — combining innovation, precision, and sustainability to fight atherosclerosis and empower researchers globally.
Founder, CEO of Fluotech Biosciences Limited
We continuously push the boundaries of science to develop groundbreaking solutions.
Together, we achieve more by leveraging the expertise of our team and partners.
We are committed to sustainable practices in all aspects of our operations, ensuring minimal environmental impact.
Transparency and honesty guide our interactions with stakeholders, partners, and the community.
We strive for excellence in every aspect of our work, from research and development to commercialization.
We are deeply committed to improving global health and advancing scientific discovery.
At FluoTech Biosciences, quality is at the heart of everything we do. We are dedicated to delivering safe, effective, and reliable nanomaterial solutions that meet the highest industry standards.
Targeted drug delivery with FTB-728 for precise, effective therapies.
Navigating global standards to ensure compliance and accelerate patient access.
Transforming cardiovascular treatment through advanced nanotechnology solutions.
Supporting research and clinical applications with reliable, scalable services.
FluoTech Biosciences is dedicated to transforming cardiovascular health through innovative nanomaterial solutions. Our mission is to address critical global health challenges.
At FluoTech, we are committed to delivering breakthrough technologies like our proprietary FTB-728 nanoparticle platform, which offers unparalleled drug-loading capacity and precise targeting capabilities as well as ATHRICINE. This dual-purpose technology serves both as a research tool and a therapeutic solution.
With leading institutions and industry partners to advance our innovative technologies and drive global impact.
At FluoTech Biosciences, we are driven by innovation, teamwork, and integrity — shaping the future of cardiovascular health through advanced nanomaterial solutions. Our commitment to excellence and sustainability fuels every discovery, collaboration, and product we bring to life. Together, we strive to make a lasting impact on global healthcare and scientific progress.